143 related articles for article (PubMed ID: 25786493)
1. Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3.
Nakajima Y; Tojo T; Morita M; Hatanaka K; Shirakami S; Tanaka A; Sasaki H; Nakai K; Mukoyoshi K; Hamaguchi H; Takahashi F; Moritomo A; Higashi Y; Inoue T
Chem Pharm Bull (Tokyo); 2015; 63(5):341-53. PubMed ID: 25786493
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.
Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
Bioorg Med Chem; 2015 Aug; 23(15):4871-4883. PubMed ID: 26071372
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.
Yamagishi H; Shirakami S; Nakajima Y; Tanaka A; Takahashi F; Hamaguchi H; Hatanaka K; Moritomo A; Inami M; Higashi Y; Inoue T
Bioorg Med Chem; 2015 Aug; 23(15):4846-4859. PubMed ID: 26059596
[TBL] [Abstract][Full Text] [Related]
4. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
Farmer LJ; Ledeboer MW; Hoock T; Arnost MJ; Bethiel RS; Bennani YL; Black JJ; Brummel CL; Chakilam A; Dorsch WA; Fan B; Cochran JE; Halas S; Harrington EM; Hogan JK; Howe D; Huang H; Jacobs DH; Laitinen LM; Liao S; Mahajan S; Marone V; Martinez-Botella G; McCarthy P; Messersmith D; Namchuk M; Oh L; Penney MS; Pierce AC; Raybuck SA; Rugg A; Salituro FG; Saxena K; Shannon D; Shlyakter D; Swenson L; Tian SK; Town C; Wang J; Wang T; Wannamaker MW; Winquist RJ; Zuccola HJ
J Med Chem; 2015 Sep; 58(18):7195-216. PubMed ID: 26230873
[TBL] [Abstract][Full Text] [Related]
5. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.
Yin Y; Chen CJ; Yu RN; Wang ZJ; Zhang TT; Zhang DY
Bioorg Med Chem; 2018 Sep; 26(17):4774-4786. PubMed ID: 30139575
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3.
Nakajima Y; Aoyama N; Takahashi F; Sasaki H; Hatanaka K; Moritomo A; Inami M; Ito M; Nakamura K; Nakamori F; Inoue T; Shirakami S
Bioorg Med Chem; 2016 Oct; 24(19):4711-4722. PubMed ID: 27544589
[TBL] [Abstract][Full Text] [Related]
8. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.
Hamaguchi H; Amano Y; Moritomo A; Shirakami S; Nakajima Y; Nakai K; Nomura N; Ito M; Higashi Y; Inoue T
Bioorg Med Chem; 2018 Oct; 26(18):4971-4983. PubMed ID: 30145050
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.
Yu RN; Chen CJ; Shu L; Yin Y; Wang ZJ; Zhang TT; Zhang DY
Bioorg Med Chem; 2019 Apr; 27(8):1646-1657. PubMed ID: 30853331
[TBL] [Abstract][Full Text] [Related]
12. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
Dugan BJ; Gingrich DE; Mesaros EF; Milkiewicz KL; Curry MA; Zulli AL; Dobrzanski P; Serdikoff C; Jan M; Angeles TS; Albom MS; Mason JL; Aimone LD; Meyer SL; Huang Z; Wells-Knecht KJ; Ator MA; Ruggeri BA; Dorsey BD
J Med Chem; 2012 Jun; 55(11):5243-54. PubMed ID: 22594690
[TBL] [Abstract][Full Text] [Related]
13. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
[TBL] [Abstract][Full Text] [Related]
14. Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.
Forster M; Chaikuad A; Dimitrov T; Döring E; Holstein J; Berger BT; Gehringer M; Ghoreschi K; Müller S; Knapp S; Laufer SA
J Med Chem; 2018 Jun; 61(12):5350-5366. PubMed ID: 29852068
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.
Jaime-Figueroa S; De Vicente J; Hermann J; Jahangir A; Jin S; Kuglstatter A; Lynch SM; Menke J; Niu L; Patel V; Shao A; Soth M; Vu MD; Yee C
Bioorg Med Chem Lett; 2013 May; 23(9):2522-6. PubMed ID: 23541670
[TBL] [Abstract][Full Text] [Related]
16. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
Norman P
Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
Bioorg Med Chem; 2016 Sep; 24(18):4517. PubMed ID: 27544046
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
Bioorg Med Chem; 2017 May; 25(10):2813. PubMed ID: 28366269
[No Abstract] [Full Text] [Related]
19. Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Mizojiri R; Nii N; Asano M; Sasaki M; Satoh Y; Yamamoto Y; Sumi H; Maezaki H
Bioorg Med Chem; 2019 Jun; 27(12):2521-2530. PubMed ID: 30879862
[TBL] [Abstract][Full Text] [Related]
20. Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models.
Carbone A; Pennati M; Parrino B; Lopergolo A; Barraja P; Montalbano A; Spanò V; Sbarra S; Doldi V; De Cesare M; Cirrincione G; Diana P; Zaffaroni N
J Med Chem; 2013 Sep; 56(17):7060-72. PubMed ID: 23919303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
